2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2872 Evaluation of obexelimab in patients with warm autoimmune hemolytic anemia: Results from the open label safety and dose confirmation run-in period of a phase 3 study

Bruno Fattizzo, MD, Gillian Evans2, Steven Lentz, MD,PhD3, Caroline Piatek, MD4, Audrey Wells, PhD5, Shauna Quinn6
1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, University of Milan, Milan, Italy
2 East Kent Hospitals University NHS Foundation Trust, Kent, United Kingdom
3 University of Iowa, Iowa City, Iowa, United States
4 University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
5 Zenas BioPharma, Waltham, Massachusetts, United States
6 Zenas BioPharma, Waltham, Massachusetts, United States

Introduction. Warm autoimmune hemolytic anemia (wAIHA) is a rare, often severe autoimmune disorder characterized by the binding of autoantibodies to red blood cells (RBCs) at core body temperature (37°C), leading to hemolysis and signs/symptoms of anemia, including severe fatigue, dyspnea, pallor, and jaundice. There are currently no FDA-approved treatments for wAIHA. The disease is typically managed with corticosteroids; however, relapses are common and long-term steroid use carries significant risk of side effects and other complications. Rituximab, a CD20-targeted B-cell depletor, demonstrated response rates of approximately 70–80% in wAIHA; however, efficacy estimates are confounded by substantial concomitant corticosteroid use in many studies, including two small, randomized trials that evaluated rituximab with an initial corticosteroid induction (1 - 1.5 mg/kg/day prednisone equivalent followed by taper) versus corticosteroids alone. In addition, as rituximab depletes B cells, patients may experience significant infectious risk.  There is a need for safe and effective therapies. Obexelimab is a humanized, bifunctional monoclonal antibody that is designed to inhibit B-cell activation and function through co-engagement of CD19 and the inhibitory receptor FcγRIIb (CD32b), without inducing cytotoxic depletion. Obexelimab is an investigational product and not approved for any indication. Here we report on the safety and efficacy of obexelimab in an open-label safety and dose confirmation run in period of a Phase 3 study in patients with wAIHA (NCT05786573).

 

Methods. The SAPHIARE study was a multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamic (PD), and efficacy (including improvement in hemoglobin (Hgb)) of obexelimab in adult patients with wAIHA on or after Week 8. Eligible patients had been clinically diagnosed with primary or secondary wAIHA due to autoimmune disorders for at least 3 months with documentation of a positive direct antiglobulin test specific for anti-IgG or anti-IgA and failed at least 1 previous wAIHA therapy. Patients were required to have at least one sign/symptom of anemia with a Hgb level of ≥ 7 to < 10 g/dL on Day 1. Patients self-administered obexelimab via weekly subcutaneous (SC) injections at the clinic or at home, depending on the study visit.

 

Results. The SAPHIARE study was terminated early because of low enrollment. Ten patients with wAIHA were enrolled in the study. The median age at the time of enrollment was 70.5 years. Seven of 10 (70.0%) of patients were female, 9/10 (90.0%) were white, and 1/10 (10.0%) was Asian. Nine of 10 patients (90.0%) had a diagnosis of primary wAIHA, while only 1 (10.0%) had secondary wAIHA, related to autoimmune hepatitis. The median disease duration was approximately 2 years, and all patients had failed at least one prior wAIHA therapy. Median Hgb at baseline was 9.25 g/dL, and 6/10 (60.0%) patients were on background therapy (including low-dose glucocorticoids, EPO, mycophenolate) at the time they entered the study

All 10 patients completed the study through Week 24.  Six of 10 (60.0%) patients experienced an improvement in hemoglobin of ≥ 1 g/dL from baseline on or after Week 8 in the absence of rescue medications in the preceding 28 days, and four (40.0%) of these patients experienced an improvement of ≥ 2 g/dL.

Six out of 10 patients (60.0%) experienced at least 1 treatment-emergent adverse event (TEAE), all but 1 were ≤ grade 2. There were 3 TEAEs considered related to obexelimab, two events of nausea and one of vomiting, and all were grade 1. There was only one serious event of cholecystitis, not related to obexelimab. There were no discontinuations due to adverse events. 


Conclusions.
The SAPHIARE study was terminated early due to slow enrollment, highlighting the difficulty in recruiting patients with wAIHA into clinical studies. Data from 10 patients in the SAPHIARE study demonstrated that weekly SC administration of obexelimab was well-tolerated and improved levels of Hgb in elderly wAIHA patients who failed at least one prior therapy.

Bruno Fattizzo, MD: Alexion, AstraZeneca, Johnson & Johnson, Novartis, Recordati, Roche, Sanofi, Sobi, Zenas BioPharma - Honoraria; Alexion, AstraZeneca, Johnson & Johnson, Novartis, Recordati, Roche, Sanofi, Sobi, Zenas BioPharma - Consultancy (Includes expert testimony)